| Current Price | $195.19 | Mkt Cap | $36.6B |
|---|---|---|---|
| Open | $194.68 | P/E Ratio | -55.83 |
| Prev. Close | $195.19 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $194.43 - $196.16 | Volume | 1,076,154 |
| 52-Wk Range | $116.08 - $207.17 | Avg. Daily Vol. | 1,597,774 |
A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.
| Current Price | $195.19 | Mkt Cap | $36.6B |
|---|---|---|---|
| Open | $194.68 | P/E Ratio | -55.83 |
| Prev. Close | $195.19 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $194.43 - $196.16 | Volume | 1,076,154 |
| 52-Wk Range | $116.08 - $207.17 | Avg. Daily Vol. | 1,597,774 |
The best Bull and Bear pitches based on recency and number of recommendations.
Sig revenue expansion opportunity from recent launches, plus potential blockbuster in ladiratuzumab vedotin moving through trials. Merck 'partnership' provides multiple opps for combination approaches.
$2.34B for a drug which treats HL and ALCL seems very, very rich, even when taking SGEN's strong balance sheet into account. Very cool platform, but the target for brentuximab vedotin is expressed on a narrow enough set of tumor types to keep this… More
Read the most recent pitches from players about SGEN.
Recs
TMFEBCapital
(71.76)
Submitted: 10/30/2020 1:35:34 PM :
Start Price:
$173.04
NASDAQ:SGEN Score:
-5.85
Sig revenue expansion opportunity from recent launches, plus potential blockbuster in ladiratuzumab vedotin moving through trials. Merck 'partnership' provides multiple opps for combination approaches.
Recs
IndyAnthony
(< 20)
Submitted: 4/20/2020 6:27:29 PM :
Start Price:
$138.94
NASDAQ:SGEN Score:
-13.83
Biotech on the rise with new breast cancer drug got the nod from the FDA.
Recs
marekz
(23.23)
Submitted: 4/20/2020 12:26:59 PM :
Start Price:
$142.79
NASDAQ:SGEN Score:
-12.85
fast progress on current lineup of promising drugs, but now has added several drugs into the pipeline that address big markets.
Find the members with the highest scoring picks in SGEN.
lloydvon (< 20) Score: +4,008.99
The Score Leader is the player with the highest score across all their picks in SGEN.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| lloydvon | < 20 | 8/30/2006 |
|
1Y | $4.48 | +4,256.92% | +247.93% | +4,008.99 | 1 Comment | |
| Zipsdad | < 20 | 10/4/2006 |
|
1Y | $4.67 | +4,079.66% | +240.92% | +3,838.74 | 0 Comment | |
| twildstar | 93.49 |
|
|
NS | $4.93 | +3,859.23% | +234.25% | +3,624.98 | 0 Comment | |
| vkowalczuk | 89.15 | 10/19/2006 |
|
1Y | $5.10 | +3,727.25% | +232.49% | +3,494.77 | 1 Comment | |
| RAIDERFAN77 | 70.72 |
|
|
1Y | $5.27 | +3,603.80% | +218.69% | +3,385.11 | 0 Comment | |
| SloopJohnB06 | 96.19 | 12/26/2006 |
|
5Y | $5.63 | +3,366.96% | +221.94% | +3,145.02 | 0 Comment | |
| muae1 | < 20 | 12/18/2006 |
|
NS | $5.76 | +3,288.72% | +218.03% | +3,070.69 | 0 Comment | |
| biogirl | < 20 | 1/8/2007 |
|
3M | $6.45 | +2,926.67% | +222.25% | +2,704.42 | 0 Comment | |
| opveiby | 80.28 | 1/8/2007 |
|
1Y | $6.46 | +2,921.52% | +222.18% | +2,699.34 | 0 Comment | |
| Turkmenbashi | 67.46 | 1/8/2007 |
|
3Y | $6.59 | +2,861.91% | +221.14% | +2,640.77 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
